E2 ModeratePreliminaryPEM unclearCase-ControlPeer-reviewedMachine draft
The increase of alpha-melanocyte-stimulating hormone in the plasma of chronic fatigue syndrome patients.
Shishioh-Ikejima, Nobue, Ogawa, Tokiko, Yamaguti, Kouzi et al. · BMC neurology · 2010 · DOI
Quick Summary
Researchers measured a hormone called alpha-MSH in the blood of 55 ME/CFS patients and compared it to 30 healthy people. They found that patients diagnosed within the last 5 years had significantly higher alpha-MSH levels than healthy controls, but this difference disappeared in patients who had been ill longer. This suggests alpha-MSH might be a useful blood test for identifying ME/CFS in newly diagnosed patients.
Why It Matters
ME/CFS lacks validated biological markers, making diagnosis challenging and reliant on clinical criteria alone. If alpha-MSH proves reliable as an early biomarker, it could improve diagnostic accuracy and enable research into the role of pituitary activation in ME/CFS pathophysiology, potentially opening new treatment targets.
Observed Findings
- Mean plasma alpha-MSH was significantly higher in CFS patients overall (17.9 pg/mL) compared to healthy controls (14.5 pg/mL, p=0.02).
- In CFS patients diagnosed ≤5 years prior, alpha-MSH levels (20.8 pg/mL) were significantly elevated versus controls (p<0.01).
- CFS patients diagnosed 5-10 years prior showed no significant difference in alpha-MSH (15.6 pg/mL) compared to healthy controls.
- A significant negative correlation existed between disease duration and alpha-MSH levels (p=0.04, rs=-0.28).
- No correlations were found between alpha-MSH and ACTH, cortisol, or DHEA-S levels.
Inferred Conclusions
- Alpha-MSH elevation may be a time-limited biological feature of early-stage ME/CFS, potentially useful as a biomarker in newly diagnosed patients.
- The decline in alpha-MSH with disease duration suggests changes in pituitary melanotroph activation over the illness course.
- Alpha-MSH may be independent of the hypothalamic-pituitary-adrenal (HPA) axis dysfunction commonly reported in ME/CFS.
Remaining Questions
- Why do alpha-MSH levels decrease over time as disease progresses, and what mechanisms drive this trajectory?
- Could alpha-MSH serve as a prognostic marker or reflect reversible early immune/neuroendocrine changes?
What This Study Does Not Prove
This study does not prove alpha-MSH causes ME/CFS or explain why levels decrease with disease duration. The wide range of values within the CFS group and lack of correlation with other hormones (ACTH, cortisol, DHEA-S) suggest alpha-MSH alone may be insufficient as a standalone diagnostic marker. The cross-sectional design cannot establish whether elevated alpha-MSH precedes illness onset or results from the disease process.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Method Flag:PEM Not DefinedSmall SampleExploratory Only
Metadata
- DOI
- 10.1186/1471-2377-10-73
- PMID
- 20731841
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →